577 related articles for article (PubMed ID: 18156171)
41. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
42. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
43. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
45. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Ghobrial IM; Munshi NC; Harris BN; Shi P; Porter NM; Schlossman RL; Laubach JP; Anderson KC; Desaiah D; Myrand SP; Wooldridge JE; Richardson PG; Abonour R
Am J Hematol; 2011 Jul; 86(7):573-8. PubMed ID: 21630305
[TBL] [Abstract][Full Text] [Related]
46. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
48. A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
[TBL] [Abstract][Full Text] [Related]
49. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
[TBL] [Abstract][Full Text] [Related]
50. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
52. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
[TBL] [Abstract][Full Text] [Related]
54. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
55. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
[TBL] [Abstract][Full Text] [Related]
57. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
58. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Zangari M; Esseltine D; Cavallo F; Neuwirth R; Elice F; Burns MJ; Yaccoby S; Richardson P; Sonneveld P; Tricot G
Am J Hematol; 2007 Sep; 82(9):831-3. PubMed ID: 17546639
[TBL] [Abstract][Full Text] [Related]
59. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
[TBL] [Abstract][Full Text] [Related]
60. Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
Song MK; Chung JS; Joo YD; Lee SM; Lee GW; Lee HS; Kim SH; Yun EY; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
Acta Haematol; 2010; 124(1):34-9. PubMed ID: 20606414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
